Updated findings on dual HER2 inhibition in HER2+ breast cancer
Researchers from the Clínic-IDIBAPS, along with researchers from the Dana Farber Cancer Institute (DFCI) in Boston, have published a review on dual H1
Researchers from the Clínic-IDIBAPS, along with researchers from the Dana Farber Cancer Institute (DFCI) in Boston, have published a review on dual H1
Five researchers from the Clínic-IDBAPS were recognized with various grants worth a total of €122,000 at the Spanish Society of Medical Oncology (SEO1
Researchers from the Clínic-IDIBAPS have coordinated a study that analyses the efficacy of anti-PD-1/PD-L1 immune checkpoint inhibitors (ICIs) combin1
One of the highlights of the Clínic-IDIBAPS participation in the European Society for Medical Oncology (ESMO) 2024 Congress was Dr. Josep M. Llovet’s1
A recent report from an organisation linked to the WHO states that talc is probably carcinogenic to humans. The use of talc is considered to increase1
This year, FERO will contribute €200,000, with which it will seek to provide structural and sustained support for the Molecular Diagnostics Programme1
The BBVA Foundation – Hospital Clínic de Barcelona Advanced Research Contracts are aimed at specialists in the Health Sciences, with experience in re1
Cryotherapy consists of cooling the scalp and avoiding one of the most visible side effects of chemotherapy.
These awards are organized by the Spanish Metastatic Breast Cancer Association to promote research in this area. The project presented by Dr. Aleix1
Removing the fallopian tubes from women undergoing other gynaecological surgery could reduce mortality from ovarian cancer by up to 14%.